Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
The RECOVERY trial will assess the safety and tolerability of 2 mg intravitreal aflibercept
injections (IAI) given monthly (Q4WK) or every 12 weeks (Q12WK) for the treatment of retinal
capillary non-perfusion (RNP) associated with proliferative diabetic retinopathy (PDR).
- Assess the safety and tolerability of IAI for the treatment of proliferative diabetic
retinopathy by evaluating the incidence and severity of ocular and systemic adverse
events through week 52
- Change in area of retinal capillary non-perfusion, as assessed by central reading
center, from baseline through week 52